. Studies performed to date with mucin-specific T-cell lines and clones have shown that CTLs recognize an immunodominant epitope formed at the junction of two tandem repeats, resulting from underglycosylation on tumor cells, and consisting of the amino acid sequence PDTRP. The same sequence is also recognized by several highly tumor-specific anti-mucin monoclonal antibodies (21-23) as well as some patients' sera (24). Depending on the inherited number of tandem repeats present in the mucin of different individuals, this epitope can be repeated 20-100 or more times per molecule. Moreover, the threedimensional structure of the repeat is very rigid with each epitope being not only a sequence repeat but also a threedimensional repeat (31, 32) . This unusual structure combined with the high epitope density appears to allow a crosslinking of the T-cell receptor and therefore a direct binding and major histocompatibility complex (MHC)-unrestricted recognition of the mucin molecule on tumor cells by specific CTLs (25) (26) (27) (28) .
advantage of their costimulatory molecules for T-cell activation. The vaccine was tested in chimpanzees because of the identity of the human and chimpanzee MUC-1 tandem repeat sequence. EBV-immortalized B cells derived from two chimpanzees were transfected with MUC-1 cDNA, treated with glycosylation inhibitor phenyl-N-acetyl-C-D-galactosaminide to expose tumor-associated epitopes, irradiated, and injected subcutaneously four times at 3-week intervals. One vaccine preparation also contained cells transduced with the interleukin 2 (IL-2) cDNA and producing low levels of IL-2. Already after the first injection we found in the peripheral blood measurable frequency of cytotoxic T-cell precursors specific for underglycosylated mucin. The highest frequency observed was after the last boost, in the lymph node draining the vaccination site. Delayed-type hypersensitivity reaction to the injected immunogens was also induced, whereas no appearance of mucin-specific antibodies was seen. Long (2, 3) . Inadequate costimulation of tumor-reactive T cells may contribute to the fact that even antigenic tumors are not normally rejected by the immune system. The best-described costimulatory molecules are those of the B7 family (4) (5) (6) (7) and the cytokine family (8, 9) , and engineered expression of these molecules by certain
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tumors has facilitated induction of tumor-specific immunity (4, (7) (8) (9) (10) . However, when tumor-associated antigens are molecularly characterized and their recognition by the immune system clearly demonstrated, an alternative approach to eliciting effective tumor-specific immunity could be by presentation of these antigens to the immune system on competent APCs, like dendritic cells (11, 12) or activated B cells (6, (13) (14) (15) (21) (22) (23) (24) and cytotoxic T cells (19, (25) (26) (27) (28) (29) (30) . Studies performed to date with mucin-specific T-cell lines and clones have shown that CTLs recognize an immunodominant epitope formed at the junction of two tandem repeats, resulting from underglycosylation on tumor cells, and consisting of the amino acid sequence PDTRP. The same sequence is also recognized by several highly tumor-specific anti-mucin monoclonal antibodies (21) (22) (23) as well as some patients' sera (24) . Depending on the inherited number of tandem repeats present in the mucin of different individuals, this epitope can be repeated 20-100 or more times per molecule. Moreover, the threedimensional structure of the repeat is very rigid with each epitope being not only a sequence repeat but also a threedimensional repeat (31, 32) . This unusual structure combined with the high epitope density appears to allow a crosslinking of the T-cell receptor and therefore a direct binding and major histocompatibility complex (MHC)-unrestricted recognition of the mucin molecule on tumor cells by specific CTLs (25) (26) (27) (28) We have also examined C0429/MUC-1 and C0507/ MUC-1, after the treatment to inhibit glycosylation, for expression of the costimulatory molecule B7.1 and two adhesion molecules, LFA-3 and ICAM-1. As is shown in Fig. 2 Table 2 . Cells treated with glycosylation inhibitor, B-LCL- tandem repeats we performed an ELISA that we had previously employed to detect MUC-1-specific antibodies in cancer patients (24) . In Fig. 4 we show that there was no increase in the serum reactivity following the vaccination protocol. As a positive control we show mucin-specific reactivity in a serum from a breast cancer patient.
DISCUSSION
This report represents an in vivo extension of our studies to design a cellular anti-tumor vaccine, based on the findings that CTLs can specifically recognize epitopes on the mucin molecule MUC-1 expressed on epithelial tumor cells (19, (25) (26) (27) (28) (29) (1996) important that this immune response resulted in no evidence of autoimmunity, as documented by normal blood chemistries and unremarkable physical examinations (not shown). It should be emphasized, however, that MUC-1 is considered an autoantigen strictly by virtue of expression of the same unmutated MUC-1 gene in both normal and tumor tissue. Immune responses that we elicited, however, are against an epitope resulting from tumor-specific underglycosylation, which does not exist and is not presented to the immune system on normal tissues.
Inasmuch as most tumor specific responses detected in cancer patients are against self molecules abberantly expressed on tumor cells, it may be possible to use similar vaccine designs to prime new populations of tumor-specific T cells. Autologous APCs, like EBV immortalized B cells, expressing tumorassociated antigens are potentially useful immunogens for induction of cellular anti-tumor responses in vivo.
